Coverage
-
May 01, 2026
A burgeoning campaign against the False Claims Act's whistleblower mechanism is suddenly center stage at the Ninth Circuit, where pharmaceutical companies say a momentous new ruling "illustrates perfectly" the constitutional concerns of U.S. Supreme Court justices regarding FCA enforcement.
2 other articles on this case.
View all »